Target intelligence / Profile preview

DNA-directed DNA polymerase alpha, delta, and epsilon (Pol α, Pol δ, Pol ε) (Pol α, Pol δ, Pol ε)

Target
Pol α, Pol δ, Pol ε
Molecular classification
Enzyme, DNA-directed DNA polymerase
01

Overview

DNA-directed DNA polymerases alpha, delta, and epsilon are the primary enzymes responsible for the high-fidelity replication of the eukaryotic nuclear genome [1]. DNA polymerase alpha (Pol α) initiates the process by synthesizing short RNA-DNA primers, which are subsequently elongated by DNA polymerase delta (Pol δ) on the lagging strand and DNA polymerase epsilon (Pol ε) on the leading strand [2][3]. These enzymes are essential for maintaining genomic integrity, with Pol δ and Pol ε possessing intrinsic 3' to 5' exonuclease activity for proofreading mismatched bases [4]. In oncology, these polymerases are the principal targets of nucleoside analog chemotherapies, which disrupt DNA synthesis in rapidly dividing cells to trigger programmed cell death [5]. Furthermore, mutations in the proofreading domains of the POLE and POLD1 genes are associated with hypermutated phenotypes in various cancers, serving as critical biomarkers for identifying patients likely to respond to immune checkpoint inhibitors [6].

Other names
DNA polymerase alpha and other replicative DNA polymerasesReplicative DNA polymerasesDNA polymerase complexPOLA1POLD1POLEEukaryotic replicative polymerases
02

Mechanism of action

Nucleoside analogs act as antimetabolites that are phosphorylated into active triphosphate forms; these compete with natural deoxynucleotide triphosphates (dNTPs) for incorporation into the nascent DNA strand by replicative polymerases, leading to DNA chain termination, replication fork stalling, and the induction of apoptosis.

03

Biological functions

DNA replicationDNA repairCell cycle progressionCell proliferationGenome maintenance
04

Disease associations

CancerColorectal cancerEndometrial cancerGenetic instability syndromesPOLE-associated proofreading deficiencyPOLD1-associated proofreading deficiency
05

Safety considerations

MyelosuppressionGastrointestinal toxicityMucositisAlopeciaNephrotoxicitySecondary malignancies
06

Interacting drugs

Cytarabine

7 more in the full profile.

07

Biomarkers

POLE mutation statusPOLD1 mutation statusMicrosatellite instability (MSI)Tumor mutational burden (TMB)PCNA expression

Beyond the preview

Go deeper on DNA-directed DNA polymerase alpha, delta, and epsilon (Pol α, Pol δ, Pol ε) (Pol α, Pol δ, Pol ε).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNA-directed DNA polymerase alpha, delta, and epsilon (Pol α, Pol δ, Pol ε) (Pol α, Pol δ, Pol ε).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call